| Aging human body: changes in bone, muscle and body fat with consequent changes in nutrient intake P JafariNasabian, JE Inglis, W Reilly, OJ Kelly, JZ Ilich Journal of Endocrinology 234 (1), R37-R51, 2017 | 365 | 2017 |
| Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer JH Strickler, H Satake, TJ George, R Yaeger, A Hollebecque, ... New England journal of medicine 388 (1), 33-43, 2023 | 320 | 2023 |
| Osteosarcopenic obesity in women: impact, prevalence, and management challenges P JafariNasabian, JE Inglis, OJ Kelly, JZ Ilich International Journal of Women's Health 9, 33-42, 2017 | 106 | 2017 |
| First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety JH Strickler, H Satake, A Hollebecque, Y Sunakawa, P Tomasini, ... Journal of Clinical Oncology 40 (36_suppl), 360490-360490, 2022 | 60 | 2022 |
| A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma DC Smith, M Kroiss, E Kebebew, MA Habra, R Chugh, BJ Schneider, ... Investigational new drugs 38, 1421-1429, 2020 | 58 | 2020 |
| Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval B Cadieux, R Coleman, P Jafarinasabian, A Lipton, RZ Orlowski, F Saad, ... Journal of Bone Oncology 33, 100416, 2022 | 41 | 2022 |
| Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p. G12C … S Ramalingam, M Fakih, J Strickler, R Govindan, BT Li, S Goldberg, ... Molecular Cancer Therapeutics 20 (12_Supplement), P05-01-P05-01, 2021 | 28 | 2021 |
| A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC … DS Hong, R Yaeger, Y Kuboki, T Masuishi, MA Barve, GS Falchook, ... Journal of Clinical Oncology 40 (4_suppl), TPS214-TPS214, 2022 | 15 | 2022 |
| Effect of varying degrees of renal impairment on the pharmacokinetics of omecamtiv mecarbil A Trivedi, RK Oberoi, P Jafarinasabian, H Zhang, S Flach, S Abbasi, ... Clinical Pharmacokinetics 60, 1041-1048, 2021 | 14 | 2021 |
| Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a … A Trivedi, W Sohn, P Kulkarni, P Jafarinasabian, H Zhang, M Spring, ... Clinical and Translational Science 14 (6), 2510-2520, 2021 | 7 | 2021 |
| Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator A Trivedi, RK Oberoi, M Mackowski, P Jafarinasabian, H Zhang, S Flach, ... Biopharmaceutics & Drug Disposition 42 (7), 319-328, 2021 | 7 | 2021 |
| How exercise and dietary intervention affect the outcome of osteosarcopenic obesity syndrome? P JafariNasabian Journal of Functional Morphology and Kinesiology 3 (2), 31, 2018 | 7 | 2018 |
| Metabolic profile of osteosarcopenic obesity syndrome: Identifying biomarkers for diagnostic criteria P JafariNasabian, JE Inglis, MP Ave, KJ Hall, SE Nieto, OJ Kelly, JZ Ilich The FASEB Journal 31, 151.5-151.5, 2017 | 7 | 2017 |
| Epcoritamab SC+ R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP … JSP Vermaat, J Brody, J Ďuraš, YH Karimi, CY Cheah, JM Darrah, ... Blood 142, 4457, 2023 | 6 | 2023 |
| Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects A Trivedi, W Sohn, CP Hsu, P Jafarinasabian, H Zhang, S Hutton, S Flach, ... Clinical Pharmacology in Drug Development 11 (3), 388-396, 2022 | 6 | 2022 |
| Pharmacokinetic evaluation of the CYP3A4 and CYP2D6 drug‐drug interaction and CYP3A4 induction potential of omecamtiv mecarbil: two open‐label studies in healthy subjects A Trivedi, FI Malik, P Jafarinasabian, H Zhang, S Flach, S Abbasi, S Dutta, ... Clinical Pharmacology in Drug Development 11 (2), 185-193, 2022 | 6 | 2022 |
| Effect of varying degrees of hepatic impairment on the pharmacokinetics of omecamtiv mecarbil A Trivedi, RK Oberoi, M Mackowski, P Jafarinasabian, H Zhang, S Flach, ... Clinical Pharmacology in Drug Development 10 (12), 1442-1451, 2021 | 6 | 2021 |
| Analyzing Bone, Muscle and Adipose Tissue Biomarkers to Identify Osteosarcopenic Obesity Syndrome in Older Women P JafariNasabian Florida State University, 2017 | 5 | 2017 |
| Adipokines as Mediators of Bone Density in Overweight/Obese Postmenopausal Women After 6‐Month Weight Loss Program P Jafarinasabian, YC Chi, J Ilich The FASEB Journal 29, 738.4, 2015 | 5 | 2015 |
| Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects A Trivedi, W Sohn, P Jafarinasabian, H Zhang, B Terminello, S Flach, ... Clinical Pharmacology in Drug Development 11 (1), 129-133, 2022 | 4 | 2022 |